GlassScriptPhysician profile
Niloofar Nobakht
NPI 1811123151
$96,672.19
in general payments reported to CMS, 2019-2025
22 companies · $47K in 2025
The $47K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $246 · 2021: $676 · 2022: $8,770 · 2023: $30K · 2024: $9,157 · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Honoraria: $27K · Travel and Lodging: $9,511 · Consulting Fee: $9,179 · Food and Beverage: $7,136 · Education: $27.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,650.00 |
| Honoraria | $26,550.00 |
| Travel and Lodging | $9,510.74 |
| Consulting Fee | $9,179.00 |
| Food and Beverage | $7,136.27 |
| Education | $27.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $34,187.65 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $31,657.27 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Astrazeneca Pharmaceuticals LP | $14,978.04 | 2019-2023 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $6,533.30 | 2019-2025 | Jynarque, Tolvaptan, Voyxact |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,679.69 | 2021-2025 | Jynarque |
| Travere Therapeutics, INC. | $2,191.30 | 2023-2025 | Filspari |
| Shield Therapeutics INC | $1,731.48 | 2022 | |
| Aurinia Pharma U.S., INC. | $1,553.35 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $244.62 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.52 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $136.64 | 2025 | Terlivaz |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | |
| Amgen INC. | $122.10 | 2025 | |
| Glaxosmithkline, LLC. | $121.90 | 2021 | |
| Baxter Healthcare | $109.22 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.76 | 2023 | Livtencity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Genzyme Corporation | $18.51 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niloofar Nobakht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.